Intravenous Pamidronate in Paget's disease - quantification of remission and relapse, and implications for efficacious dosage

D.H. Gutteridge; B.G.A. Stuckey; R.W. Retallack; G.O. Stewart; G.N. Kent; R.I. Price; L.C. Ward; Richard Prince; R.I. Thompson; C.I. Bhagat; G.C. Nicholson

Intravenous Pamidronate in Paget's disease - quantification of remission and relapse, and implications for efficacious dosage

D.H. Gutteridge, B.G.A. Stuckey, R.W. Retallack, G.O. Stewart, G.N. Kent, R.I. Price, L.C. Ward, Richard Prince, R.I. Thompson, C.I. Bhagat, G.C. Nicholson

Research output: Chapter in Book/Conference paper › Conference paper

Original language	English
Title of host publication	Sixteenth Annual Meeting of the American Society for Bone and Mineral Research
Place of Publication	New York
Publisher	Mary Ann Liebert Inc
Pages	S425
Volume	9 Supplement 1
Publication status	Published - 1994
Event	Intravenous pamidronate in Paget's disease quantification of remission and relapse, and implications for efficacious dosage - Duration: 1 Jan 1994 → …

Conference

Conference	Intravenous pamidronate in Paget's disease quantification of remission and relapse, and implications for efficacious dosage
Period	1/01/94 → …

Cite this

Gutteridge, D. H., Stuckey, B. G. A., Retallack, R. W., Stewart, G. O., Kent, G. N., Price, R. I., Ward, L. C., Prince, R., Thompson, R. I., Bhagat, C. I., & Nicholson, G. C. (1994). Intravenous Pamidronate in Paget's disease - quantification of remission and relapse, and implications for efficacious dosage. In Sixteenth Annual Meeting of the American Society for Bone and Mineral Research (Vol. 9 Supplement 1, pp. S425). Mary Ann Liebert Inc.

@inproceedings{63508a1650794551ac9ed54cd863b292,

title = "Intravenous Pamidronate in Paget's disease - quantification of remission and relapse, and implications for efficacious dosage",

author = "D.H. Gutteridge and B.G.A. Stuckey and R.W. Retallack and G.O. Stewart and G.N. Kent and R.I. Price and L.C. Ward and Richard Prince and R.I. Thompson and C.I. Bhagat and G.C. Nicholson",

year = "1994",

language = "English",

volume = "9 Supplement 1",

pages = "S425",

booktitle = "Sixteenth Annual Meeting of the American Society for Bone and Mineral Research",

publisher = "Mary Ann Liebert Inc",

address = "United States",

note = "Intravenous pamidronate in Paget's disease quantification of remission and relapse, and implications for efficacious dosage ; Conference date: 01-01-1994",

}

Gutteridge, DH, Stuckey, BGA, Retallack, RW, Stewart, GO, Kent, GN, Price, RI, Ward, LC, Prince, R, Thompson, RI, Bhagat, CI & Nicholson, GC 1994, Intravenous Pamidronate in Paget's disease - quantification of remission and relapse, and implications for efficacious dosage. in Sixteenth Annual Meeting of the American Society for Bone and Mineral Research. vol. 9 Supplement 1, Mary Ann Liebert Inc, New York, pp. S425, Intravenous pamidronate in Paget's disease quantification of remission and relapse, and implications for efficacious dosage, 1/01/94.

Intravenous Pamidronate in Paget's disease - quantification of remission and relapse, and implications for efficacious dosage. / Gutteridge, D.H.; Stuckey, B.G.A.; Retallack, R.W. et al.
Sixteenth Annual Meeting of the American Society for Bone and Mineral Research. Vol. 9 Supplement 1 New York: Mary Ann Liebert Inc, 1994. p. S425.

Research output: Chapter in Book/Conference paper › Conference paper

TY - GEN

T1 - Intravenous Pamidronate in Paget's disease - quantification of remission and relapse, and implications for efficacious dosage

AU - Gutteridge, D.H.

AU - Stuckey, B.G.A.

AU - Retallack, R.W.

AU - Stewart, G.O.

AU - Kent, G.N.

AU - Price, R.I.

AU - Ward, L.C.

AU - Prince, Richard

AU - Thompson, R.I.

AU - Bhagat, C.I.

AU - Nicholson, G.C.

PY - 1994

Y1 - 1994

M3 - Conference paper

VL - 9 Supplement 1

SP - S425

BT - Sixteenth Annual Meeting of the American Society for Bone and Mineral Research

PB - Mary Ann Liebert Inc

CY - New York

T2 - Intravenous pamidronate in Paget's disease quantification of remission and relapse, and implications for efficacious dosage

Y2 - 1 January 1994

ER -